Inhibition of 11β-Hydroxysteroid dehydrogenase-1 with AZD4017 in patients with nonalcoholic steatohepatitis or nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled, phase II study.

MLA

Yadav, Yogesh, et al. “Inhibition of 11β-Hydroxysteroid Dehydrogenase-1 with AZD4017 in Patients with Nonalcoholic Steatohepatitis or Nonalcoholic Fatty Liver Disease: A Randomized, Double-Blind, Placebo-Controlled, Phase II Study.” Diabetes, Obesity & Metabolism, vol. 24, no. 5, May 2022, pp. 881–90. EBSCOhost, https://doi.org/10.1111/dom.14646.

APA

Yadav, Y., Dunagan, K., Khot, R., Venkatesh, S. K., Port, J., Galderisi, A., Cobelli, C., Wegner, C., Basu, A., Carter, R., & Basu, R. (2022). Inhibition of 11β-Hydroxysteroid dehydrogenase-1 with AZD4017 in patients with nonalcoholic steatohepatitis or nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled, phase II study. Diabetes, Obesity & Metabolism, 24(5), 881–890. https://doi.org/10.1111/dom.14646

Chicago

Yadav, Yogesh, Kelly Dunagan, Rachita Khot, Sudhakar K Venkatesh, John Port, Alfonso Galderisi, Claudio Cobelli, et al. 2022. “Inhibition of 11β-Hydroxysteroid Dehydrogenase-1 with AZD4017 in Patients with Nonalcoholic Steatohepatitis or Nonalcoholic Fatty Liver Disease: A Randomized, Double-Blind, Placebo-Controlled, Phase II Study.” Diabetes, Obesity & Metabolism 24 (5): 881–90. doi:10.1111/dom.14646.